The abstract is read at the publisher; the summary is JClub's.
Dectin-1 and Dectin-2–targeted DectiSomes liposomes loaded with amphotericin B bind strongly to Aspergillus fumigatus, Candida albicans, Cryptococcus neoformans, and Rhizopus delemar, killing them while reducing amphotericin B dose by more than an order of magnitude.
- Why it matters: New antifungal therapies are urgently needed because these priority fungal pathogens account for most fungal disease-related deaths and can cause meningitis with mortality approaching 99%.
- What they did: The work developed receptor-targeted, drug-loaded liposomes using host-pathogen receptors, then tested binding and killing across four fungal pathogens and evaluated efficacy in murine infection models.
- The result: DectiSomes were more effective in murine fungal infection, and malleable brain-delivery versions improved treatment of cryptococcal meningitis, suggesting potential for targeted therapy across fungal meningitis forms.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.